Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts-Reference-Cited by-同舟云学术

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

Published:2014-11 Issue:11 Volume:38 Page:1332-1341
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Srivastava Pragya,Paluch Benjamin E.,Matsuzaki Junko,James Smitha R.,Collamat-Lai Golda,Karbach Julia,Nemeth Michael J.,Taverna Pietro,Karpf Adam R.,Griffiths Elizabeth A.^ORCID

Funder

Astex Pharmaceuticals

NCI Cancer Center

Roswell Park Alliance Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference54 articles.

1. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia;Estey;Leukemia,2013

2. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy;Jabbour;Cancer,2010

3. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure;Prebet;J Clin Oncol,2011

4. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure;Prebet;Br J Haematol,2012

5. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure;Prebet;Haematologica,2013

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches to anticancer therapy based on modulation of DNA methylation;Siberian journal of oncology;2024-09-09

2. Integrative epigenome-transcriptome analysis unravels cancer-specific over-expressed genes potentially regulating immune microenvironment in clear cell renal cell carcinoma;Biochimica et Biophysica Acta (BBA) - General Subjects;2024-05

3. Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis;Cancer Medicine;2024-04

4. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review;Genes;2023-04-06

5. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells;Journal of Experimental & Clinical Cancer Research;2023-03-18